CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

被引：1
|
作者：
Xuan, Jiachen [1 ,2 ]
Pearson, Richard B. [1 ,2 ,3 ,4 ]
Sanij, Elaine [1 ,2 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[3] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia
[4] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia
[5] Univ Melbourne, Dept Clin Pathol, Parkville, Vic, Australia
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2020年 / 7卷 / 06期
基金：
英国医学研究理事会;
关键词：
Ovarian cancer; PARPI; drug resistance; CX-5461;
D O I：
10.1080/23723556.2020.1805256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition
    Lawrence, Mitchell G.
    Porter, Laura H.
    Choo, Nicholas
    Pook, David
    Grummet, Jeremy P.
    Pezaro, Carmel J.
    Sandhu, Shahneen
    Ramm, Susanne
    Luu, Jennii
    Bakshi, Andrew
    Goode, David L.
    Sanij, Elaine
    Pearson, Richard B.
    Hannan, Ross D.
    Simpson, Kaylene J.
    Taylor, Renea A.
    Risbridger, Gail P.
    Furic, Luc
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (11) : 2140 - 2150
  • [2] CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition
    Lawrence, Mitchell G.
    Porter, Laura H.
    Choo, Nicholas
    Sanij, Elaine
    Taylor, Renea
    Pearson, Richard
    Simpson, Kaylene J.
    Hannan, Ross D.
    Sandhu, Shahneen
    Furic, Luc
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (06)
  • [3] Inhibition of autophagy potentiates cytotoxicity of CX-5461 treatment in chemoresistant epithelial ovarian cancer
    Cornelison, Robert
    Llaneza, Danielle C.
    Petrova, Yulia
    Dobbin, Zachary C.
    Schneider, David A.
    Landen, Charles N.
    CANCER RESEARCH, 2017, 77
  • [4] Targeting RNA-polymerase I using CX-5461 as a mechanism for treating chemotherapy resistant epithelial ovarian cancer
    Cornelison, Robert
    Dobbin, Zachary C.
    Katie, Ashwini A.
    Jeong, Dae Hoon
    Petrova, Yulia
    Llaneza, Danielle C.
    Steg, Adam D.
    Zhang, Yinfeng
    Schneider, David A.
    Landen, Charles N.
    CANCER RESEARCH, 2016, 76
  • [5] CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
    Cornelison, Robert
    Biswas, Kuntal
    Llaneza, Danielle C.
    Harris, Alexandra R.
    Sosale, Nisha G.
    Lazzara, Matthew J.
    Landen, Charles N.
    CANCERS, 2021, 13 (20)
  • [6] Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
    Haddach, Mustapha
    Schwaebe, Michael K.
    Michaux, Jerome
    Nagasawa, Johnny
    O'Brien, Sean E.
    Whitten, Jeffrey P.
    Pierre, Fabrice
    Kerdoncuff, Pauline
    Darjania, Levan
    Stansfield, Ryan
    Drygin, Denis
    Anderes, Kenna
    Proffitt, Chris
    Bliesath, Josh
    Siddiqui-Jain, Adam
    Omori, May
    Huser, Nanni
    Rice, William G.
    Ryckman, David M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (07): : 602 - 606
  • [7] Impact of RNA polymerase I inhibitor CX-5461 on viral kinase-dependent and -independent cytomegalovirus replication
    Westdorp, Kristen N.
    Terhune, Scott S.
    ANTIVIRAL RESEARCH, 2018, 153 : 33 - 38
  • [8] The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans
    Kaur, Amandeep
    Hannan, Katherine M.
    Nazir, Samina
    Maclachlan, Kylee H.
    Poortinga, Gretchen
    Man, Si Ming
    Harrison, Simon
    Hannan, Ross D.
    Gardiner, Elizabeth E.
    BLOOD, 2019, 134
  • [9] CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
    Elaine Sanij
    Katherine M. Hannan
    Jiachen Xuan
    Shunfei Yan
    Jessica E. Ahern
    Anna S. Trigos
    Natalie Brajanovski
    Jinbae Son
    Keefe T. Chan
    Olga Kondrashova
    Elizabeth Lieschke
    Matthew J. Wakefield
    Daniel Frank
    Sarah Ellis
    Carleen Cullinane
    Jian Kang
    Gretchen Poortinga
    Purba Nag
    Andrew J. Deans
    Kum Kum Khanna
    Linda Mileshkin
    Grant A. McArthur
    John Soong
    Els M. J. J. Berns
    Ross D. Hannan
    Clare L. Scott
    Karen E. Sheppard
    Richard B. Pearson
    Nature Communications, 11
  • [10] BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCAmutant ovarian cancer
    Gupta, Nitasha
    Huang, Tzu-Ting
    Nair, Jayakumar. R. R.
    An, Daniel
    Zurcher, Grant
    Lampert, Erika. J. J.
    McCoy, Ann
    Cimino-Mathews, Ashley
    Swisher, Elizabeth. M. M.
    Radke, Marc. R. R.
    Lockwood, Christina. M. M.
    Reichel, Jonathan. B. B.
    Chiang, Chih-Yuan
    Wilson, Kelli. M. M.
    Cheng, Ken Chih-Chien
    Nousome, Darryl
    Lee, Jung-Min
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (701)
12345